Introduction
The proliferation, differentiation, survival and maturation of hematopoietic cells are regulated through the binding of hematopoietic growth factors to their cognate receptor on the cell surface. Formation of an activated receptor complex leads to tyrosine phosphorylation of intracellular substrates and activation of numerous signaling pathways such as the JAK/STAT and Ras/Raf/MAP kinase pathways (Ihle, 1996) . Although the precise mechanism by which receptors become activated is not fully understood, an essential feature appears to be ligand-induced homo-or heterodimerization of receptor chains or conformational change of pre-formed oligomers (Heldin, 1995; Ihle, 1996; Livnah et al., 1999) .
Acute myeloid leukemia (AML) has a multi-step pathogenesis. Transformation of a hematopoietic cell to a leukemic cell is thought to require acquisition of at least two abnormalities involving a loss of growth/ survival control and a block in myeloid differentiation. Activating mutations of signaling pathways that result in a survival or growth advantage to the immortalised leukemic clone are known to occur in AML, e.g. in the ras gene (Byrne and Marshall, 1998) , and it has therefore been hypothesized that mutations of hematopoietic growth factor receptors may also contribute to this process (Gonda and D'Andrea, 1997) . A number of mutant receptors have been reported which lend support to this suggestion, the prototype being the Val664Glu mutation of the rat Neu oncogene (Bargmann et al., 1986) . Most of the mutations confer growth factor independence on factor-dependent cell lines and are thought to activate receptor by mimicking ligand binding. In some mutants this is probably achieved by induction of receptor dimerization in the absence of ligand through point mutations which introduce stable bonds, either in the extracellular dimer interface as described for the erythropoietin receptor (EpoR) and thrombopoietin receptor c-MPL (Alexander et al., 1995; Watowich et al., 1994; Yoshimura et al., 1990) or in the transmembrane (TM) domain as reported in the bc chain common to the granulocytemacrophage colony stimulating factor (GM-CSF)/ interleukin (IL)-3/IL-5 receptors and c-MPL (Jenkins et al., 1995 (Jenkins et al., , 1998 Onishi et al., 1996) . However, although these mutations have proved to be tumorigenic when injected into syngeneic mice (Alexander et al., 1995; Jenkins et al., 1995; Onishi et al., 1996; Yoshimura et al., 1990) , they have all been created by random or targeted mutagenesis in vitro. To date, the activating mutations detected in blast cells from primary leukemic patients have all been in the tyrosine kinase receptors, in particular the stem cell factor (SCF) receptor c-kit, and FLT3 (Beghini et al., 2000; Kiyoi et al., 1999; Kottaridis et al., 2001) . No activating mutations have been reported in the non tyrosine kinase receptors of the hematopoietin receptor superfamily which includes many of the receptors involved in myelopoiesis (Alexander and Nicola, 1998) .
In a study of the G-CSF receptor (G-CSFR) in 40 AML patients, we previously reported identifying a base change which would potentially cause a threonine to asparagine substitution at amino acid 617 in the TM domain (Bernard et al., 1996) . It was not clear, however, whether this base change was a leukemiaspecific mutation or an infrequent polymorphism because no remission blood or bone marrow, constitutive DNA or family members were available for study. We have therefore screened a large cohort of AML patients and, having unequivocally demonstrated that the mutation is leukemia-specific, have investigated the functional consequences of the mutant receptor.
Results

Presence of the mutant receptor in AML
The Thr617Asn base change was originally identified in an AML patient with FAB type M1 who had since died and had no living relatives (Bernard et al., 1996) . Semi-quantitative PCR with a mismatch primer and HincII digestion showed that the mutant was 32% of total G-CSFR in peripheral blood from the first patient. The blast cell count was 48%, suggesting that most of them were heterozygous for the mutation (Figure 1 ). To determine whether it was an infrequent polymorphism or a leukemia-specific mutation, we screened this nucleotide of the G-CSFR in genomic DNA from a further 515 patients at presentation with AML. The mutation was identified in peripheral blood from one patient with FAB type M2 at a level of 13% of total. The blast count was 53% which suggested that the mutant allele was present in approximately 50% of the circulating blast cells. It was not present in remission bone marrow from this patient, indicating that it was leukemia-specific. Furthermore, it was not detected in a relapse bone marrow sample 8 months after remission (Figure 1 ), suggesting that it was a secondary abnormality which was acquired in an already transformed cell.
The mutant receptor binds G-CSF and can be internalized
Ba/F3 cells were transfected with either wild type (WT) or mutant (MUT) G-CSFR cDNA and surface expression determined by binding of biotinylated G-CSF. Pools of cells were used for all experiments. Ligand binding was detected in all transfected cells compared to native (untransfected) cells (Figure 2a ) and was competed out by the addition of excess G-CSF (data not shown). However, the overall level of ligand binding to WT transfectants was consistently greater than to MUT transfectants (Figure 2a) . In two pairs of independently prepared transfectants, mean cell fluorescence (MCF) for ligand binding gave a WT/ MUT ratio of 1.99+0.24 and 2.73+0.66 respectively (mean+s.d. of three separate analyses). Western blots of cell lysates confirmed that this reflected a greater amount of expressed WT than MUT receptor (data not shown). To examine receptor internalization, cells were pre-incubated with or without 10 ng/ml G-CSF at 378C for varying times, acid washed, then binding of biotinylated G-CSF determined. Both WT and MUT transfectants internalized receptor, but the rate of down-regulation of MUT receptor was more rapid than WT receptor (n=3, P=0.024, two-tailed paired t-test) (Figure 2b ).
The mutant receptor confers growth factor independence on a factor-dependent cell line
The viability and growth of pools of transfectants in the presence of 1% FCS and either no added growth factors, 10 ng/ml G-CSF or murine (m)IL-3 was assessed by trypan blue exclusion and [ 3 H]thymidine uptake. WT transfectants all died within three days in the absence of growth factors whereas the MUT transfectants demonstrated growth factor independence ( Figure 3a) . In order to be sure that this was not due to the outgrowth of a clone of cells which had spontaneously acquired growth factor independence, viability assays were performed on three separate transfections. Growth factor independence was observed in all MUT but not WT transfectants, whereas in the presence of G-CSF or mIL-3, viability and growth of the WT and MUT transfectants were similar (Figure 3b) . [
3 H]thymidine uptake demonstrated that in the absence of added factors, growth was 3.2% of that obtained in mIL-3 for WT transfectants and 62.6% for MUT transfectants (mean of two independent experiments) ( Figure 3c ). Nevertheless, this mutant receptor proliferation was not maximal and could be increased with the addition of G-CSF.
Signaling from the mutant receptor
Starved Ba/F3 transfectants were stimulated at 378C with or without either 100 ng/ml G-CSF for varying Figure 1 Demonstration of the mutation by restriction enzyme digestion of radioactively labeled PCR products. The TM domain of the G-CSFR was amplified from genomic DNA of a normal control (NC), AML patients at presentation (P), complete remission (CR) and relapse (R), digested with HincII and the products separated by PAGE times or 10 ng/ml mIL-3 for 10 min and protein lysates prepared. Western blots were probed with phosphospecific antibodies against STAT1, STAT3, STAT5, ERK1 and ERK2 (New England Biolabs, Beverly, MA, USA), then stripped and re-probed with the relevant total antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) ( Figure 4 ). Weak constitutive tyrosine phosphorylation of STAT3 was observed in the MUT but not WT transfectants and this was enhanced by the addition of G-CSF (Figure 4b ). Phosphorylation of STAT1 and STAT5 was only apparent in the presence of G-CSF in both WT and MUT cells (Figure 4a ,c). The kinetics of activation for all 3 STATs were similar in both WT and MUT transfectants, with maximal activation at 5 -10 min. Very weak constitutive phosphorylation of both ERK1 and ERK2 was present in the MUT transfectants and was enhanced by the addition of G-CSF (Figure 4d ).
Lysates from transfectants that were either unstimulated or stimulated with 100 ng/ml G-CSF for 3 min or 10 ng/ml mIL-3 for 10 min were immunoprecipitated with antibodies against JAK2 (UBI, Lake Placid, NY, USA) or the G-CSFR (Santa Cruz Biotechnology). Western blots were probed with PY99, a phosphotyrosine specific antibody (Santa Cruz Biotechnology), then stripped and re-probed with antibody against JAK2 or the receptor. Weak tyrosine phosphorylation of both JAK2 (Figure 5a ) and the G-CSFR itself ( Figure 5b ) was observed in cells transfected with MUT but not WT receptor, and this could be significantly increased by stimulation with G-CSF.
Starved Ba/F3 transfectants were stimulated with increasing concentrations of G-CSF for 3 min at 378C and Western blots of the resulting lysates probed with phospho-specific antibodies for STAT3 and STAT5. Weak phosphorylation of STAT3 was observed with G-CSF stimulation at 1 ng/ml in the WT transfectants and this was significantly enhanced at 10 ng/ml, whereas in the MUT transfectants, a low level of phosphorylation was present at 0, 0.1 and 1 ng/ml G-CSF which was significantly increased at 10 ng/ml G-CSF (Figure 6a ). The pattern of STAT5 phosphorylation appeared to be similar in the WT and MUT transfectants, with phosphorylation only detectable at 10 ng/ml G-CSF ( Figure 6b ).
The mutant receptor induced G-CSF independent myeloid differentiation in primary cells
The effect of the mutant receptor on the fate of primary hematopoietic stem cells was studied by retrovirally transducing human CD34 + cells with either control vector (MSCV), WT or MUT G-CSFR cDNA, all linked to the marker gene EGFP, then maintained in liquid culture in the absence or presence of 100 ng/ml G-CSF. Two independent experiments were performed. Transduction efficiency was assessed by gating for EGFP positivity on the flow cytometer and, although variable, was approximately equal in the G-CSFR transduced cells for any one experiment. Mean EGFP positivity was 14.5% and 21.1% respectively for MSCV-WT and MSCV-MUT cells in experiment 1, 57.4% and 68.3% in experiment 2, but was very low for MSCV transduced cells in both experiments, 3.9% and 5.4% respectively.
In the cultures grown without G-CSF, MSCV-MUT cells showed greater evidence of differentiation than the MSCV-WT cells. For example, in experiment 2 at day 11 of culture in the absence of G-CSF, 8% of total MSCV-WT and 51% of total MSCV-MUT cells were morphologically identifiable as neutrophils, whereas in the presence of G-CSF, 70% and 75% respectively were neutrophils (Figure 7 ). To evaluate this further, expression of the myelomonocytic surface antigens CD11b and CD14 was determined by immunophenotyping and flow cytometry. Scattergrams were corrected for non-specific binding of the isotype control antibody and the results expressed as a proportion of EGFP + cells (Table 1) . Transduced cells expressing CD11b or CD14 increased over the time studied in all cultures. At each time point, the percentage of EGFP + cells expressing CD11b or CD14 was approximately the same in all cells grown in the presence of G-CSF, irrespective of the transduction, and for any one transduction this value was consistently higher than in the same cells grown in + is significantly greater than MSCV-WT transduced cells for cells grown in the absence but not the presence of G-CSF (P=0.04 and 0.39 respectively, two-tailed paired t-test). CD14 expression shows the same trend but does not reach the same level of significance (P=0.09 and 0.70 in the absence and presence of G-CSF respectively). These results demonstrated that the mutant receptor did not inhibit myeloid differentiation, indeed it appeared to induce differentiation in the absence of ligand.
Discussion
Although evidence is now accumulating that constitutively activating mutations in growth factor receptors may be common as a cause of uncontrolled prolifera- Figure 4 Phosphorylation pattern of STATs 1, 3 and 5 and ERKs 1 and 2 in lysates from Ba/F3 transfectants. Cells were stimulated with or without 100 ng/ml G-CSF for varying times or 10 ng/ml mIL-3 for 10 min. Western blots of the lysates were probed with phospho-specific antibodies, stripped and re-probed with total antibodies. Longer exposures are shown at the end of some lanes tion in primary leukemic cells, to date, the mutations identified in patients have all occurred in receptors with intrinsic tyrosine kinase activity (Robertson et al., 2000) . In AML, such mutations are common in FLT3 and involve the juxtamembrane domain or the activation loop (Abu-Duhier et al., 2001; Kiyoi et al., 1999; Kottaridis et al., 2001; Yamamoto et al., 2001) . The Thr617Asn mutation identified in the TM domain of the G-CSFR of our two AML patients is therefore the first activating mutation detected in primary hematopoietic cells which involves a non-tyrosine kinase receptor that is dependent on activation of intracellular tyrosine kinases such as JAKs for downstream signaling events. A similar oncogenic TM mutation (Ser498Asn) was reported in c-MPL (Onishi et al., 1996) , but this mutation was created by random mutagenesis and has not been detected in AML patients (Kitamura et al., 1998) . In one of our patients the mutation was not present in remission, indicating that it was acquired in the leukemic clone (Figure 1) . Furthermore, it did not reappear at relapse, suggesting that it was unlikely to be involved in the initial transformation of the malignant cell as it was not requisite for the leukemic phenotype. However, it may have contributed to disease progression by providing an enhanced growth or survival advantage in a subclone, thus expanding it to a level at which it could be detected. Several reports have demonstrated that both N-Ras and FLT3 mutations can also be lost at relapse (Farr et al., 1988; Kottaridis et al., 2002; Nakano et al., 1999) , suggesting that instability of secondary mutations may be a common feature of AML.
Ba/F3 cells transfected with G-CSFR MUT DNA were growth factor independent ( Figure 3 ) and had constitutive phosphorylation of JAK2, STAT3, the receptor itself and both ERK1 and ERK2 (Figures 4  and 5 ). G-CSF binding considerably enhanced all these signals and induced phosphorylation of STAT1 and STAT5. The low level of constitutive phosphorylation in the MUT cells relative to the G-CSF induced signals was particularly striking in view of the fact that this was sufficient to cause nearly 70% of the optimal G-CSF induced growth (Figure 3c ), and sustained proliferation over at least a 2 week period in the absence of growth factors was feasible (data not shown). The pattern and sensitivity of growth response to G-CSF was similar in WT and MUT transfectants; the relative increase in proliferation of the WT transfectants between 0.1 ng/ml and 1 ng/ml G-CSF Figure 5 Tyrosine phosphorylation of (a) anti-JAK2 and (b) anti-G-CSFR immunoprecipitates from Ba/F3 transfectants stimulated with or without 100 ng/ml G-CSF for 3 min or 10 ng/ ml mIL-3 for 10 min. Lysates were immunoprecipitated with anti-JAK2 or anti-G-CSFR antibodies; blots were probed with the phospho-tyrosine specific antibody PY99, stripped and reprobed with antibody against JAK2 or G-CSFR Figure 6 Dose-dependent phosphorylation of STATs 3 and 5 in Ba/F3 transfectants stimulated with varying concentrations of G-CSF for 3 min. Western blots were probed with phospho-specific antibodies against STAT3 and STAT5, stripped and reprobed with total antibodies Figure 7 May-Grunwald Giemsa staining of cytospin preparations from purified human umbilical cord CD34 + cells retrovirally transduced with MSCV-WT or MSCV-MUT and cultured in the absence or presence of 100 ng/ml G-CSF for 11 days was 42.5% of optimal growth in the WT transfectants and 50.4% in the GR-MUT transfectants. It is therefore unlikely that the growth observed in the GR-MUT transfectants in the absence of added factors reflects a hypersensitivity to minute amounts of growth factors in the reduced (1%) serum of the culture conditions rather than true growth factor independence. These results were reflected in the relative level of STAT3 activation at differing G-CSF concentrations: a detectable increase in phosphorylation was only observed at 1 ng/ml G-CSF in both WT and MUT cells (Figure 6a) . Activated STAT3 by itself can mediate cellular transformation (Bromberg et al., 1999) , but the presence of constitutively activated STAT3 as a consequence of the G-CSFR mutant is of interest as the role of different STATs in G-CSF induced signaling is controversial. Some reports suggest that it is STAT5 activation which is critical for G-CSF induced proliferation and survival (Dong et al., 1998; Ilaria et al., 1999) whereas activation of STAT3 is important for differentiation of myeloid cells in response to G-CSF (Shimozaki et al., 1997; Ward et al., 1999) . Others have reported that activation of STAT3 is necessary for G-CSF induced proliferative signals and contributes to G-CSF induced differentiation (McLemore et al., 2001) . No constitutive activation of STAT5 was observed in the present studies which suggests that activation of STAT3 is sufficient for proliferative responses resulting from activation of the G-CSFR, although we cannot exclude the possibility that very low levels of STAT5 activation below the level of detection were present.
Retroviral transduction of WT or MUT receptor into primary hematopoietic cells demonstrated that the mutant receptor did not interfere with G-CSF dependent differentiation. In the presence of G-CSF, the cells developed into morphologically recognizable neutrophils ( Figure 7 ) which expressed CD11b or C14 (Table 1 ). In the absence of G-CSF, the MSCV-MUT transduced cells demonstrated a greater degree of myeloid differentiation than the MSCV-WT transduced cells. This was reflected both in the level of neutrophils observed and in the statistically significant increase in CD11b expression. The proportion of EGFP + CD11b + cells grown without G-CSF in the two experiments was 83% and 81% respectively of the same cells grown with G-CSF for MSCV-MUT cells compared to 22% and 37% for MSCV-WT cells (Table 1) . Similar results were obtained for EGFP + CD14 + expression. Although STAT phosphorylation was not analysed in these cells, extrapolation from the data obtained using Ba/F3 cells would suggest that activation of STAT3 is therefore also sufficient to lead to myeloid differentiation induced through activation of the G-CSFR, which is consistent with the results from others (McLemore et al., 2001) .
The functional consequence of activating mutations will depend on when the relevant receptor is expressed, the level of its expression and whether this is sustained or transient as the cell differentiates. G-CSFR expression is low in multipotential hematopoietic stem cells and increases with myeloid differentiation (McKinstry et al., 1997; Shinjo et al., 1995) . Expression of MUT receptor was always significantly lower than that of the WT receptor which may be due to the more rapid internalization of MUT receptor (Figure 2b) . Studies of the transferrin receptor have similarly demonstrated that introduction of polar residues into TM domains of cell surface receptors can modulate their downregulation (Zaliauskiene et al., 2000) . Irrespective of the mechanism, these results indicate that low levels of the Thr617Asn mutant receptor were sufficient to lead to growth factor independent proliferation of primary hematopoietic cells. Although early hematopoietic cells show little proliferative response to G-CSF alone, in vitro and in vivo studies have shown that it synergises with SCF to induce a significant increase in CFU-GM growth and circulating neutrophils (Bernstein et al., 1991; Molineux et al., 1991) . Therefore, the mutant receptor is likely to drive myeloproliferation in circumstances where growth factors are limiting. The observation that point mutations in the TM domain can lead to constitutively active receptors suggests that this sequence plays a critical role in receptor function and is not simply important for anchoring the receptor in the cell surface membrane. Ligand binding to the extracellular domain promotes receptor dimerization through TM helix -helix association, and studies have shown that asparagine residues can strongly drive helix association within a membrane-like environment and promote structural stability (Choma et al., 2000; Zhou et al., 2000) . Although receptor dimerization is essential for receptor function, it is not necessarily sufficient for receptor activation, and ligand binding is required to induce a conformational change in the receptor which brings the associated JAK2 molecules into sufficiently close proximity to allow trans-phosphorylation and activation of downstream pathways (Livnah et al., 1999; Remy et al., 1999) . The asparagine in the G-CSFR mutant may therefore not only stabilize the formation of dimers but also induce sufficient conformational change to allow weak JAK2 trans-phosphorylation, which is nevertheless adequate to support proliferation and differentiation. However, our results suggest that this interaction is not rigid and the conformational change can be altered or increased by ligand binding to the extracellular domain, leading to much more efficient JAK2 and receptor activation.
The G-CSFR mutation reported here was leukemiaassociated but it was only detected in two out of 555 AML patients, although it should be pointed out that the screening method employed was specifically for this mutation and would not pick up other potentially activating mutations in the same region. This G-CSFR mutation supports the in vitro models postulated for TM helix -helix interactions (Choma et al., 2000; Zhou et al., 2000) and demonstrates that only very low levels of receptor activation are necessary to provide a growth signal which may lead to enhanced myeloproliferation which is a step in the pathogenesis of leukemia.
Materials and methods
Mutation screening
Genomic DNA from peripheral blood or bone marrow of 515 AML patients at diagnosis (six FAB type M0, 99 M1, 100 M2, 110 M3, 100 M4, 100 M5) was screened for the mutation using PCR with a mismatch primer which introduced a cutting site for HincII in products containing the mutant sequence. A fragment of 361 bp was amplified (primers 5'-TGGGCCTGTTCGGCCTCCTGCTGTTGGT-CA-3' with mismatch underlined and 5'-CTGTGAGCT-GGGTCTGGGAC-3' covering nucleotides 15275 -15635 of the G-CSFR DNA sequence, GenBank accession 14733086) with 30 cycles, each 30 s at 958C, 30 s at 648C, 30 s at 728C and a final extension of 5 min at 728C. The mixture contained 100 ng DNA, 16Taq polymerase buffer, 2.25 mM MgCl 2 , 200 mM dNTPs, 10 pmols each primer and 1U Taq polymerase (Promega, Madison, WI, USA). PCR products were digested with HincII at 378C then electrophoresed through a 2% agarose gel. Semi-quantitative PCR was performed using a 32 P-labeled primer with 25 cycles as above. Digested PCR products were separated on 6% polyacrylamide gels and the signals were quantified using a Hoefer densitometer (Hoefer Scientific Instruments, San Francisco, CA, USA).
Plasmid construction of mutant
A construct containing the WT G-CSFR cDNA sequence in pLNCX was a kind gift from Dr Ivo Touw, Rotterdam. The MUT construct containing C2086A was created using a sitedirected mutagenesis kit (Stratagene, La Jolla, CA, USA) and the complete coding region sequenced.
Ba/F3 transfections
Ba/F3 cells were grown in RPMI 1640 supplemented with 10% fetal calf serum (FCS), 50 U/ml penicillin, 50 mg/ml streptomycin (pen/strep) and 10% WEHI-conditioned medium as a source of murine (m)IL-3. Approximately 25 mg WT or MUT DNA was transfected into 8610 6 cells by electroporation at 960 mFD and 400 V and positive cells selected with 1 mg/ml G418 (Gibco BRL, Paisley, UK). Pools of cells were used for all experiments.
G-CSF binding and ligand-induced receptor down-regulation
Native cells and transfectants (4610 6 /ml in PFN (PBS, 2% FCS, 0.1% sodium azide)) were incubated for 1 h on ice with 200 ng/ml biotinylated human G-CSF (Chugai Pharmaceutical Co, Japan) in the presence or absence of 1000-fold excess cold G-CSF. The cells were then washed with ice-cold PFN, incubated with 400 ng/ml Streptavidin-RED670 TM second layer (Gibco BRL) for 1 h on ice, washed and analysed by flow cytometry. To examine ligand-induced internalization, transfectants (4610 6 /ml) were incubated in PBS with 5 mM glucose, 2% BSA+10 ng/ml G-CSF for varying times at 378C, acid washed in ice-cold PBS pH 3.0 for 2 min, washed with ice-cold PFN then incubated with biotinylated G-CSF and treated as above.
Cell growth
Ba/F3 transfectants were washed four times and resuspended at 2610 5 cells/ml in RPMI 1640, 1% FCS, pen/strep and either no added growth factor, 10 ng/ml G-CSF or 10 ng/ml mIL-3. Densities were adjusted daily to 2610 5 /ml. Viability was determined by trypan blue exclusion. For 
Immunoprecipitation and Western blotting
Ba/F3 transfectants were washed four times, incubated 5 h at 378C in reduced (1%) serum without growth factors, then resuspended in PBS at 10610 6 /ml and stimulated at 378C+growth factors as specified. The reaction was stopped with ice-cold PBS and the pelleted cells incubated in lysis buffer (20 mM Tris pH 7.5, 137 mM NaCl, 1% NP40, 10% glycerol, 20 mM NaF, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonylfluoride and 10 mg/ml each of aprotinin, leupeptin and pepstatin) at 10610 6 /ml for 30 min on ice. For cell lysates an equal volume of 26Laemmli sample buffer was added and the sample boiled. For immunoprecipitates the supernatant was incubated overnight at 48C with the relevant antibody, then protein A-agarose beads (Repligen, Cambridge, MA, USA), washed, resuspended in 26Laemmli sample buffer and boiled. Proteins were separated on SDS -PAGE and transferred to nitrocellulose membrane (Hybond C-extra; Amersham Pharmacia Biotech). Blots were incubated in PFT (5% polyvinylpyrrolidone, 2% FCS in TBST (Tris-buffered saline (50 mM Tris pH 8.0, 200 mM NaCl) containing 0.05% Tween-20) to block non-specific binding then probed with primary antibody. After washing with TBST, blots were incubated with peroxidase-conjugated secondary antibody (Dakopatts, High Wycombe, UK), washed with TBST and then visualized using enhanced chemiluminescence (Amersham Pharmacia Biotech). Blots were stripped in 0.1 M glycine pH 2.5, washed in TBST and reprobed as specified.
Construction of retroviral vectors and producer cell lines
WT and MUT cDNAs were subcloned into the bicistronic retroviral vector MSCV-IRES-EGFP (MSCV) (Persons et al., 1999) . Vector particles pseudotyped with the VSV-G envelope protein were generated by transfection of 293T cells (Persons et al., 1998) and used to introduce vector alone (MSCV), MSCV-WT or MSCV-MUT transgene into the FLYRD18 packaging cell line to create polyclonal populations of RD114 producer cells (Kelly et al., 2000) . Conditioned media were prepared by incubating 20 ml Dulbecco's modified Eagle's medium containing 10% FCS with confluent producer cells in 175 cm 2 culture flasks for 24 h at 378C, harvested and passed through 45 mM filters, then used fresh or stored at 7808C until needed. Viral titers, determined by analysing EGFP expression in HeLa cells transduced with serial dilutions of conditioned medium, were 1 -5610 5 functional particles/ml. Integrity of the transgene in the producer and HeLa cells was confirmed by Southern blot analysis.
CD34
+ cell transduction and phenotyping
Mononuclear cells were recovered from human umbilical cord blood by density gradient centrifugation through FicollPaque TM PLUS (Amersham Pharmacia Biotech). CD34 + cells were purified to 490% purity using anti-CD34 + bound beads according to the manufacturer's instructions (Miltenyi Biotec, Bergisch Gladbach, Germany) and immediately incubated at 2 -4610 5 /ml in a prestimulation medium (IMDM containing 20% FCS, pen/strep, 300 ng/ml FLT3 ligand, 300 ng/ml SCF, 10 ng/ml IL-3 and 10 ng/ml IL-6) at 378C for 24 h. Six-well plates coated with RectroNectin 1 (Takara Biomedicals, Japan) were pre-incubated with 362 ml loadings of MSCV, MSCV-WT or MSCV-MUT conditioned medium, each 30 min at room temperature, then CD34+ cells in prestimulation medium were added at approximately 5610 5 well and incubation continued for 24 h at 378C. The cells were harvested and resuspended in IMDM containing 20% FCS, 20 ng/ml SCF, +100 ng/ml G-CSF (hereafter referred to as day 0 of culture), then counted every 2 -3 days and passaged with IMDM containing 20% FCS+100 ng/ml G-CSF to maintain a density of 2 -4610 5 / ml. Cytospin preparations were assessed morphologically by May-Grunwald-Giesma staining. Surface marker immunophenotyping was performed using allophyocyanin-conjugated mouse anti-human antibodies against CD11b, CD14 and an isotype-matched IgG1 control (Caltag Laboratories, Burlingame, CA, USA). Cells (2610 5 ) were incubated with 2 -4 ml antibody for 1 h on ice, washed with PBS, fixed with 2% formaldehyde and analysed by flow cytometry.
